|
1
|
Saltz LB, Cox JV, Blanke C, et al:
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Imamura Y, Lochhead P, Yamauchi M, et al:
Analyses of clinicopathological, molecular and prognostic
associations of KRAS codon 61 and codon 146 mutations in colorectal
cancer: cohort study and literature review. Mol Cancer. 13:1352014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buchler T, Pavlik T, Melichar B, et al:
Bevacizumab with 5-fluorouracil, leucovorin and oxaliplatin versus
bevacizumab with capecitabine and oxaliplatin for metastatic
colorectal carcinoma: results of a large registry-based cohort
analysis. BMC Cancer. 14::3232014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saif MW: Antiangiogenesis therapy in
second line metastatic colorectal cancer: similar but different.
Expert Opin Biol Ther. 13:1489–1493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung GG, Yoon HH, Zerkowski MP, et al:
Vascular endothelial growth factor, FLT-1 and FLK-1 analysis in a
pancreatic cancer tissue microarray. Cancer. 106:1677–1684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bellamy WT, Richter L, Frutiger Y and
Grogan TM: Expression of vascular endothelial growth factor and its
receptors in hematopoietic malignancies. Cancer Res. 59:728–733.
1999.PubMed/NCBI
|
|
8
|
Daenen LG, Roodhart JM, van Amersfoort M,
et al: Chemotherapy enhances metastasis formation via
VEGFR-1-expressing endothelial cells. Cancer Res. 71:6976–6985.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YJ, Karl DL, Maduekwe UN, et al:
Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor
metastases based on host organ environment. Cancer Res.
70:8357–8367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity, metastasis and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
|
11
|
Fenton C, Patel A, Dinauer C, Robie DK,
Tuttle RM and Francis GL: The expression of vascular endothelial
growth factor and the type 1 vascular endothelial growth factor
receptor correlate with the size of papillary thyroid carcinoma in
children and young adults. Thyroid. 10:349–357. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato H, Yoshikawa M, Miyazaki T, et al:
Expression of vascular endothelial growth factor (VEGF) and its
receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Anticancer Res. 22:3977–3984. 2002.PubMed/NCBI
|
|
13
|
Tanigaki Y, Nagashima Y, Kitamura Y,
Matsuda H, Mikami Y and Tsukuda M: The expression of vascular
endothelial growth factor-A and -C and receptors 1 and 3:
correlation with lymph node metastasis and prognosis in tongue
squamous cell carcinoma. Int J Mol Med. 14:389–395. 2004.PubMed/NCBI
|
|
14
|
Dales JP, Garcia S, Bonnier P, et al:
Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and
VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol. 23:297–305.
2003.(In French). PubMed/NCBI
|
|
15
|
Secord AA, Darcy KM, Hutson A, et al:
Gynecologic Oncology Group study: Co-expression of angiogenic
markers and associations with prognosis in advanced epithelial
ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol.
106:221–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamilton SR and Aaltonen LA: World Health
Organization Classification of TumoursPathology and Genetics of
Tumors of the Digestive System. IARC Press; Lyon, France: 2000
|
|
17
|
Itakura J, Ishiwata T, Shen B, Kornmann M
and Korc M: Concomitant over-expression of vascular endothelial
growth factor and its receptors in pancreatic cancer. Int J Cancer.
85:27–34. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Delmotte P, Martin B, Paesmans M, et al:
VEGF and survival of patients with lung cancer: a systematic
literature review and meta-analysis. Rev Mal Respir. 19:577–584.
2002.(In French). PubMed/NCBI
|
|
19
|
Bando H, Weich HA, Brokelmann M, et al:
Association between intratumoral free and total VEGF, soluble
VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer.
92:553–561. 2005.PubMed/NCBI
|
|
20
|
Wang L, Liu X, Wang H and Wang S:
Correlation of the expression of vascular endothelial growth factor
and its receptors with microvessel density in ovarian cancer. Oncol
Lett. 6:175–180. 2013.PubMed/NCBI
|
|
21
|
Boiocchi L, Vener C, Savi F, et al:
Increased expression of vascular endothelial growth factor receptor
1 correlates with VEGF and microvessel density in Philadelphia
chromosome-negative myeloproliferative neoplasms. J Clin Pathol.
64:226–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okita NT, Yamada Y, Takahari D, et al:
Vascular endothelial growth factor receptor expression as a
prognostic marker for survival in colorectal cancer. Jpn J Clin
Oncol. 39:595–600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhan P, Wang J, Lv XJ, et al: Prognostic
value of vascular endothelial growth factor expression in patients
with lung cancer: a systematic review with meta-analysis. J Thorac
Oncol. 4:1094–1103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen G, Ding J, Luo L, et al: Expression
of vascular endothelial growth factor and its receptors in
laryngeal carcinoma cell and its significance. Lin Chuang Er Bi Yan
Hou Ke Za Zhi. 19:842–844. 2005.(In Chinese). PubMed/NCBI
|
|
25
|
Fan F, Wey JS, McCarty MF, et al:
Expression and function of vascular endothelial growth factor
receptor-1 on human colorectal cancer cells. Oncogene.
24:2647–2653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhukova LG, Zhukov NV and Lichinitser MR:
Expression of Flt-1 and Flk-1 receptors for vascular endothelial
growth factor on tumor cells as a new prognostic criterion for
locally advanced breast cancer. Bull Exp Biol Med. 135:478–481.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dhakal HP, Naume B, Synnestvedt M, et al:
Expression of vascular endothelial growth factor and vascular
endothelial growth factor receptors 1 and 2 in invasive breast
carcinoma: prognostic significance and relationship with markers
for aggressiveness. Histopathology. 61:350–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kopparapu PK, Boorjian SA, Robinson BD, et
al: Expression of VEGF and its receptors VEGFR1/VEGFR2 is
associated with invasiveness of bladder cancer. Anticancer Res.
33:2381–2390. 2013.PubMed/NCBI
|
|
29
|
Seibold ND, Schild SE, Bruchhage KL,
Gebhard MP, Noack F and Rades D: Prognostic impact of VEGF and
FLT-1 receptor expression in patients with locally advanced
squamous cell carcinoma of the head and neck. Strahlenther Onkol.
189:639–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sha D and He YJ: Expression and clinical
significance of VEGF and its receptors Flt-1 and KDR in
nasopharyngeal carcinoma. Ai Zheng. 25:229–234. 2006.(In Chinese).
PubMed/NCBI
|
|
31
|
Rades D, Setter C, Dunst J, Dahl O, Schild
SE and Noack F: Prognostic impact of VEGF and VEGF receptor 1
(FLT1) expression in patients irradiated for stage II/III non-small
cell lung cancer (NSCLC). Strahlenther Onkol. 186:307–314. 2010.
View Article : Google Scholar : PubMed/NCBI
|
